methotrexate + nimotuzumab

Methotrexate is a small molecule antimetabolite that inhibits dihydrofolate reductase, thereby interfering with DNA synthesis and cell proliferation. Nimotuzumab is a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR), blocking EGFR signaling pathways involved in tumor cell growth and survival. The combination of methotrexate and nimotuzumab is not widely reported as a standard regimen but may be considered for certain cancers where both agents have activity, such as head and neck squamous cell carcinoma or nasopharyngeal carcinoma[3][4][8]. This combination aims to enhance antitumor effects by combining cytotoxic chemotherapy with targeted therapy. There are no major published clinical trials specifically evaluating this exact combination; most studies combine nimotuzumab with other chemotherapies like docetaxel, cisplatin, or 5-fluorouracil[3][4][8].

Other names

methotrexate and nimotuzumabnimotuzumab plus methotrexate